Models adjusted for significant biomarker and clinical covariates (age, BMI, hypertension, cholesterol, LDL-C, triglycerides, apoB and apoE) as a function of LpA-I:A-II levels revealed continued significance of LpA-I:A-II levels (hazard ratio 5.31, 95% CI 1.12–25.17, p = 0.036) as a predictor of risk in the HR2 subgroup. This evidence concerns the gene APOE and hypertensive disorder.